X4 Pharmaceuticals, Inc.

Greetings, and welcome to X4 Pharmaceuticals' second quarter financial and operating results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin.

Thank you, Operator, and good morning, everyone. Presenting on today's call will be X4's Chief Executive Officer, Dr. Paul Regan, and the company's Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open up the call to your questions, and we'll be joined by Chief Scientific Officer, Art Tavares, Chief Medical Officer, Tego Kadavid, and Chief Operating Officer, Mary DiBiase. As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development plans, as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Description of these risks can be found in X4's most recent filings with the SEC, including this quarter's 10-Q, which is expected to be filed after market close today. I'd now like to turn the call over to X4's President and CEO, Dr. Paula Regan.

Paula?